

CEL-SCI Corp (CVM) - Financial and Strategic SWOT Analysis Review

URL:	https://marketpublishers.com/r/CB3DBAA8B17EN.html
Date:	January 30, 2018
Pages:	41
Price:	US\$ 125.00
ID:	CB3DBAA8B17EN

CEL-SCI Corp (CVM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company's operations and business divisions.
- Corporate strategy – Analyst's summarization of the company's business strategy.
- SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives' employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

CEL-SCI Corp (CEL-SCI) is a biotechnology company that carries out the research and development of new immunotherapy products for the treatment of various cancer and infectious diseases. Its core capabilities include drug discovery, research, development and manufacturing of compound biological substances. CEL-SCI's lead candidate Multikine (leukocyte interleukin), is an investigational immunotherapy against cancer and human papilloma virus (HPV). The company is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 in hospitalized patients and vaccines CEL-2000 and CEL-4000 for rheumatoid arthritis using its Ligand Epitope Antigen Presentation System (LEAPS) technology platform. CEL-SCI is headquartered in Vienna, Virginia, the US.

CEL-SCI Corp Key Recent Developments

Dec 29,2017: CEL-SCI Reports Fiscal 2017 Financial Results and Clinical & Corporate Developments

Dec 18,2017: CEL-SCI Announces Robert Watson Joins its Board of Directors

Sep 19,2017: CEL-SCI Announces \$1.5 Million NIH SBIR Grant to Support Development of Rheumatoid

Arthritis Vaccine

Aug 09,2017: CEL-SCI Reports Third Quarter Fiscal Year 2017 Financial Results

May 10,2017: CEL-SCI Reports Second Quarter Fiscal Year 2017 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Content

SECTION 1 - ABOUT THE COMPANY

CEL-SCI Corp - Key Facts
CEL-SCI Corp - Key Employees
CEL-SCI Corp - Key Employee Biographies
CEL-SCI Corp - Major Products and Services
CEL-SCI Corp - History
CEL-SCI Corp - Company Statement
CEL-SCI Corp - Locations And Subsidiaries
Head Office

SECTION 2 – COMPANY ANALYSIS

Company Overview

CEL-SCI Corp - Business Description
CEL-SCI Corp - Corporate Strategy
CEL-SCI Corp - SWOT Analysis
SWOT Analysis - Overview
CEL-SCI Corp - Strengths
CEL-SCI Corp - Weaknesses
CEL-SCI Corp - Opportunities
CEL-SCI Corp - Threats
CEL-SCI Corp - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
CEL-SCI Corp, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Dec 29, 2017: CEL-SCI Reports Fiscal 2017 Financial Results and Clinical & Corporate Developments
Dec 18, 2017: CEL-SCI Announces Robert Watson Joins its Board of Directors
Sep 19, 2017: CEL-SCI Announces \$1.5 Million NIH SBIR Grant to Support Development of Rheumatoid Arthritis Vaccine
Aug 09, 2017: CEL-SCI Reports Third Quarter Fiscal Year 2017 Financial Results
May 10, 2017: CEL-SCI Reports Second Quarter Fiscal Year 2017 Financial Results
Feb 27, 2017: CEL-SCI Announces That the NYSE MKT Approves Plan
Feb 09, 2017: CEL-SCI Reports First Quarter Fiscal 2017 Financial Results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

CEL-SCI Corp, Key Facts
CEL-SCI Corp, Key Employees
CEL-SCI Corp, Key Employee Biographies
CEL-SCI Corp, Major Products and Services
CEL-SCI Corp, History
CEL-SCI Corp, Key Competitors
CEL-SCI Corp, Ratios based on current share price
CEL-SCI Corp, Annual Ratios

CEL-SCI Corp, Annual Ratios (Cont.1)
CEL-SCI Corp, Interim Ratios
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
CEL-SCI Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

CEL-SCI Corp, Performance Chart (2013 - 2017)
CEL-SCI Corp, Ratio Charts
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

COMPANIES MENTIONED

Aduro BioTech Inc
Biopolymer Innovations Llc
ImmunoGen Inc
Lentigen Technology Inc
Threshold Pharmaceuticals Inc

I would like to order:

Product name: CEL-SCI Corp (CVM) - Financial and Strategic SWOT Analysis Review
Product link: <https://marketpublishers.com/r/CB3DBAA8B17EN.html>
Product ID: CB3DBAA8B17EN
Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/CB3DBAA8B17EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
E-mail:
Company:
Address:
City:
Zip/Post Code:
Country:
Tel:
Fax:
Your message:

* All fields are required

Customer Signature _____

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms_conditions.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**